open access

Vol 12, No 6 (2017)
Review Papers
Published online: 2017-12-29
Get Citation

My patient treated with sulodexide — when and why I use this drug?

Iwona Gorczyca, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2017.0109
·
Folia Cardiologica 2017;12(6):580-588.

open access

Vol 12, No 6 (2017)
Review Papers
Published online: 2017-12-29

Abstract

Venous thromboembolism (VTE) is a frequent cause of death, both its first manifestation and subsequent recurrences. The risk of the recurrence is highest in patients with unprovoked VTE and in those with deep vein thrombosis in the proximal segment. After an obligatory 3-month anticoagulant therapy, indications for long-term anticoagulant therapy should be considered in patients with VTE. The paper presents the current state of knowledge on the prophylaxis of recurrences and a case report describing the daily choices made in patients at highest cardiovascular risk.

Abstract

Venous thromboembolism (VTE) is a frequent cause of death, both its first manifestation and subsequent recurrences. The risk of the recurrence is highest in patients with unprovoked VTE and in those with deep vein thrombosis in the proximal segment. After an obligatory 3-month anticoagulant therapy, indications for long-term anticoagulant therapy should be considered in patients with VTE. The paper presents the current state of knowledge on the prophylaxis of recurrences and a case report describing the daily choices made in patients at highest cardiovascular risk.
Get Citation

Keywords

sulodexide, deep vein thrombosis

About this article
Title

My patient treated with sulodexide — when and why I use this drug?

Journal

Folia Cardiologica

Issue

Vol 12, No 6 (2017)

Pages

580-588

Published online

2017-12-29

DOI

10.5603/FC.2017.0109

Bibliographic record

Folia Cardiologica 2017;12(6):580-588.

Keywords

sulodexide
deep vein thrombosis

Authors

Iwona Gorczyca
Beata Wożakowska-Kapłon

References (26)
  1. Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-dimer levels, and ultrasonography: a management study. Arch Intern Med. 1996; 156(5): 531–536.
  2. Partsch H, Kechavarz B, Mostbeck A, et al. Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. J Vasc Surg. 1996; 24(5): 774–782.
  3. Pesavento R, Lusiani L, Visonà A, et al. [Prevalence of clinically silent pulmonary embolism in deep venous thrombosis of the legs]. Minerva Cardioangiol. 1997; 45(7-8): 369–375.
  4. Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. 1999; 116(4): 903–908.
  5. Bénard E, Lafuma A, Ravaud P. [Epidemiology of venous thromboembolic disease]. Presse Med. 2005; 34(6): 415–419.
  6. Stein DP, Hull RD, Kayali F, et al. Venous thromboembolism according to age. Arch Intern Med. 2004; 164(20): 2260–2265.
  7. Zawilska K. Komentarz do zaktualizowanych polskich Wytycznych profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej. Med Prakt. 2005; 6: 157–167.
  8. Tomkowski W, Kuca P, Urbanek T, et al. Żylna choroba zakrzepowo-zatorowa-wytyczne profilaktyki, diagnostyki i terapii. Konsensus Polski 2017. Acta Angiol. 2017; 23: 73–113.
  9. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2): 315–352.
  10. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2): 199–205.
  11. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010; 8(11): 2436–2442.
  12. Palareti G, Cosmi B, Legnani C, et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006; 355(17): 1780–1789.
  13. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012; 10(6): 1019–1025.
  14. Eichinger S, Heinze G, Kyrle PA, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010; 121(14): 1630–1636.
  15. Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016; 6(5): e011190.
  16. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010; 153(8): 523–531.
  17. Andreozzi GM, Bignamini AA, Davì G, et al. SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015; 132(20): 1891–1897.
  18. Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367(21): 1979–1987.
  19. Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012; 366(21): 1959–1967.
  20. Schulman S, Kearon C, Kakkar AK, et al. RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013; 368(8): 709–718.
  21. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26): 2499–2510.
  22. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808.
  23. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010; 53(12): 2646–2655.
  24. Coccheri S, Scondotto G, Agnelli G, et al. Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23(13): 1057–1065.
  25. Gaddi A, Galetti C, Illuminati B, et al. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996; 24(5): 389–406.
  26. Piaggesi A, Abbruzzese L, Mattaliano C, et al. Sulodexide as Adjunctive Therapy in Diabetic Foot Patients With Critical Limb Ischemia Treated With Percutaneous Transluminal Angioplasty. Int J Low Extrem Wounds. 2014; 13(2): 103–109.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl